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Fournier’s gangrene (FG) is a clinically relevant condition in South 
Africa (SA), particularly at regional and district-level hospitals, where 
most affected patients present. Although relatively rare, it has a high 
mortality rate of up to 30%.[1] Failure to make the correct diagnosis 
or delay in initiating definitive management can have a devastating 
impact on the chance of survival. It is important for doctors to 
recognise the condition and have the necessary clinical tools to 
accurately assess patients with FG and decide which of them need 
urgent referral to a tertiary centre.
FG is a polymicrobial infection of the perineum, scrotum and 
penis that spreads in fascial planes and causes obliterative endarteritis 
of subcutaneous arteries, resulting in gangrene of the overlying 
tissue and skin.[2] Patients with FG usually have underlying impaired 
immunity as is seen in diabetes mellitus (DM), HIV infection and 
AIDS, chronic alcoholism, liver disease, renal disease and immune 
suppression after a transplant.[3,4] SA has the highest prevalence of 
HIV in the world,[5] and a positive correlation between HIV infection 
and FG has already been established.[6]
FG is most commonly caused by polymicrobial infection of aerobes 
and anaerobes. These usually include Escherichia coli, Streptococcus 
spp., Staphylococcus spp., Clostridium spp., Bacteroides spp. and 
Corynebacterium spp.[1] Other rare causes such as fungal infection[7] 
and atypical bacteria[8] have been described. The organisms may be 
skin flora, which act synergistically and invade and spread in the 
subcutaneous tissue because of the immunocompromised status of 
the host. There may also be an initiating event such as a periurethral 
abscess, urethral stricture, skin abscess or perianal abscess. In 
hospitalised patients, hospital-acquired methicillin-resistant S. aureus 
may cause FG.[9] FG generally affects men but can affect women, and 
it can occur at any age.
The necrotising fasciitis of FG involves the superficial and deep 
fascial planes of the perineum. The overlying skin may be involved, 
but the muscular structures deep to the fascia and the testes are usually 
spared because they have an independent blood supply. Scarpa’s 
fascia is continuous with Colles fascia (the superficial perineal fascia), 
and Dartos fascia of the penis and scrotum. This fascial plane is in 
continuity from the perineum to the clavicles. Infection of any of the 
perineal structures can progress into the superficial perineal space 
and access the fascial planes, with the potential to spread and involve 
the perineum, scrotum and penis and the abdominal wall up to the 
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clavicles.[10] Fig. 1 shows a patient with FG of the penis, scrotum and 
perineum at the time of debridement in theatre.
Management of FG is aggressive and multimodal, consisting 
of resuscitation, broad-spectrum antibiotics and surgical debride-
ment. [1,3] Diversion of urine and stool may be necessary. Some patients 
may require intensive care unit (ICU) admission. Furthermore, 
repeated debridement[11] and specialised wound care are necessary 
in some patients. The Fournier’s Gangrene Severity Index (FGSI) [2] is 
one of several assessment tools that can be used to assess the severity 
of FG.
Objectives
To review the management and outcomes of FG, compare outcomes 
in patients with DM and HIV-positive patients, identify prognostic 
factors that may contribute to decision-making in the management 
of FG, and assess the validity of the FGSI in SA patients.
Methods
Grey’s Hospital is a tertiary 530-bed academic hospital in Pieter-
maritzburg, SA. It has a wide catchment area covering a population 
of ~3 million people. It is the tertiary referral centre for urology for 
the entire referral area, which includes primary healthcare clinics 
and district and regional hospitals. All patients treated for FG in the 
Department of Urology at Grey’s Hospital between 1 January 2010 
and 31 December 2014 were included in the study. A retrospective 
chart review was performed. Patient records were traced from the 
emergency department, ward, theatre and ICU. Parameters recorded 
included age, gender, comorbidities, metabolic parameters, serum 
haematological parameters, serum biochemical parameters, extent 
of debridement, number of re-debridements, organisms cultured, 
ICU admission, management, length of hospital stay and outcome. 
Diagnosis was made on the basis of history and clinical examination.
The FGSI[1] was calculated for each patient using Microsoft Excel 
365, 2016 release (Microsoft, USA). The index was automatically 
calculated on insertion of the relevant parameters. Table 1 outlines 
the parameters used to calculate the FGSI.
In the original study in which the FGSI was described in patients 
from New York, USA, patients with an FGSI of >9 had a 75% 
probability of death. Those with an FGSI of ≤9 had a 78% probability 
of survival.[2] In the present study, a combination of FGSI >9, 
debridement beyond the perineum and requirement for organ 
support were assessed together as a predictor for mortality. These 
were chosen because they are highly clinically relevant and suitable 
to calculate quickly at the bedside.
Ethics approval for the study was granted by the Biomedical 
Research Ethics Committee of the University of KwaZulu-Natal (ref. 
no. BCA237/15).
Statistical analysis
Data were collected and tabulated using Microsoft Excel 365, 2016 
release (Microsoft, USA). Statistical analyses were performed using 
the Statistical Package for Social Sciences (SPSS) version 24 (IBM, 
USA). Comparison of means was performed using the t-test for 
equality of means in independent samples. Pearson’s χ2 test was used 
to compare categorical variables. If the projected frequency, assuming 
a true null hypothesis, in a cell of a two-by-two table was less than 
five observations, Fisher’s exact test was used. A p-value <0.05 
(5%) was considered statistically significant. Multiple univariate 
logistic regressions were performed to determine the odds ratio for 
risk factors for mortality. Following identification of risk factors, 
multivariate regression analysis was performed to confirm the 
significance of independent risk factors. Because of quasi-complete 
separation in the data resulting from the small sample size of patients 
who died, this was done using the Firth logistic regression.Fig. 1. Fournier’s gangrene involving the penis, scrotum and perianal area.
Table 1. Calculation matrix for the Fournier’s gangrene severity index[1]
Point assignment
Physiological variable
High abnormal values Normal 
(0)
Low abnormal values
+4 +3 +2 +1 +1 +2 +3 +4
Temperature (oC) ≥41 39 - 40.9 - 38.5 - 38.9 36 - 38.4 34 - 35.9 32 - 33.9 30 - 31.9 ≤29.9
Heart rate (bpm) ≥180 140 - 179 110 - 139 - 70 - 109  - 55 - 69 40 - 54 ≤39
Respiratory rate (/min) ≥50 35 - 49 - 25 - 34 12 - 24 10 - 11 6 - 9  - ≤5
Serum sodium (mmol/L) ≥180 160 - 179 155 - 159 150 - 154 130 - 149  - 120 - 129 111 - 119 ≤110
Serum potassium (mmol/L) ≥7 6 - 6.9 - 5.5 - 5.9 3.5 - 5.4 3 - 3.4 2.5 - 2.9  - <2.5
Serum creatinine (µmol/L) (double 
allocated score for acute renal failure)
≥310 177 - 309 133 - 176 - 53 - 175  - <53  - -
Haematocrit (%) ≥60 - 50 - 59.9 46 - 49.9 30 - 45.9  - 20 - 29.9  - <20
White blood count (× 109/L) ≥40 - 20 - 49.9 15 - 19.9 3 - 14.9  - 1 - 2.9  - <1
Serum bicarbonate, venous (mmol/L) ≥52 41 - 51.9 - 32 - 40.9 22 - 31.9  - 18 - 21.9 15 - 17.9 <15
bpm = beats per minute.
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Results
During the 5-year study period, a total of 44 patients (8.8 patients 
per year) were diagnosed with and treated for FG. Of these, 43 were 
male and 1 was female. The mean age was 51 years (range 28 - 82).
Comorbidities
Fig. 2 illustrates the distribution of comorbid risk factors for FG. 
There were no patients on immunosuppressive medication.
The mean age of the HIV-positive patients was 41 years and that of 
the non-HIV-positive patients 60 years (p<0.001). Similarly, the mean 
age of the DM patients was 62 years and that of the non-DM patients 
43 years (p<0.001).
Initiating events
Table 2 summarises the precipitating events leading to FG.
The two patients who developed FG after surgery initially 
underwent urethroplasty and inguinal hernia repair.
Presentation
The clinical parameters on presentation are summarised in Table 3.
Only two patients presented with an initial mean arterial pressure 
<70 mmHg. These two and three others went on to require inotrope 
support for septic shock during or after surgical management. 
Renal failure was present in 34.1% of patients, the majority of which 
(93.3%) was due to acute kidney injury (AKI). Eight patients (18.2%) 
were acidotic on presentation with a pH <7.35.
Causative organisms and antibiotic use
In 33 patients (75.0%), there was a positive culture on wound swab. 
The commonest cultured organism was S. aureus (39.4%), followed 
by Acinetobacter spp. (33.3%), S. pyogenes (24.2%) and Proteus 
mirabilis (3.0%). Most patients had evidence of urinary tract infection 
(79.6%), with E. coli cultured in the urine in 63.6% of patients and 
P. mirabilis in 15.9%. There was no concordance between culture 
findings on wound swab and in urine.
All patients were treated with broad-spectrum antibiotics, 
the majority (72.7%) per the local protocol with amoxicillin and 
clavulanic acid (co-amoxiclav), metronidazole and gentamicin. The 
remainder (27.3%) were treated with co-amoxiclav alone.
Management
All the patients were catheterised by suprapubic (84.1%) or urethral 
(15.9%) catheter placement.
All but one of the patients (97.7%) underwent surgical debridement. 
The patient who did not undergo surgical debridement was HIV-
positive and quadriplegic with infected bedsores. He presented 
18  days after initial signs of infection, in septic shock. He was not 
taken to theatre based on a multidisciplinary team decision that he 
was too ill to survive extensive debridement.
At debridement, fasciitis involving the penis and scrotum was 
found in all patients. In 72.7% of patients, the fasciitis extended 
posterior to the perineal body and debridement of the perianal area 
was also required. In 31.8% of patients, the fasciitis had spread to the 
anterior abdominal wall and debridement of the inguinal areas and 
abdominal wall was required. Fasciitis extended to the chest wall in 
one patient and down the thighs in another.
The mean number of surgical procedures per patient was 1.33 
(range 1 - 3), and 29.6% of patients required multiple debridements. 
The mean surgical time was 81 minutes (range 33 - 240). Three 
patients (6.8%) had a diverting colostomy performed at the discretion 
of the surgical team, specifically for the indication of involvement 
of the anal sphincter. Orchidectomy was performed in four patients 
(9.1%).
Twenty patients (45.5%) required blood transfusion. The mean 
number of units transfused in these patients was 2.7 (range 1 - 6).
Fig. 3 shows a patient with FG immediately after extensive debride-
ment of the left iliac fossa, and Fig. 4 shows the same patient after 
wound care, prior to skin grafting.
Outcomes
The mean hospital length of stay (LoS) was 26 days (range 9 - 48).
The overall mortality rate was 11.4%. Two of the five patients who 
died had DM, two were HIV-positive and one had both DM and 
HIV. All the patients who died had fasciitis extending beyond the 
perineum. The patients with fasciitis extending onto the thighs and to 
the chest wall both died. Patients who died did so on average within 
7 days of admission to the tertiary centre.
Six patients (13.6%) were identified as requiring ICU admission 
based on the need for organ support. Owing to severe constraints 
Neither HIV nor
DM 18.2%
DM 34.1%
HIV 40.9%
DM and
HIV 6.8%
Fig. 2. Distribution of comorbid risk factors.
Table 2. Precipitating events leading to Fournier’s gangrene 
(N=44)
Precipitating event n (%)
Periurethral abscess or urethral stricture 25 (56.8)
Perianal source, e.g. perianal abscess 10 (22.7)
Spinal cord-injured patients, e.g. with septic bedsores 3 (6.8)
Idiopathic 3 (6.8)
Post-surgical 2 (4.5)
Scrotal source, e.g. scrotal abscess 1 (2.3)
Table 3. Clinical parameters on presentation
Parameter Mean Median Range
Mean arterial pressure 
(mmHg)
95.27 95.67 63 - 130
Heart rate (bpm) 97 96 72 - 120
Temperature (oC) 36.9 36.8 35.3 - 39.1
pH on arterial blood gas 7.37 7.38 7.22 - 7.48
Lactate (mmol/L) 2.15 2.1 1 - 4.2
Haemoglobin (g/dL) 10.57 11.9 3.7 - 14.5
Creatinine (µmol/L) 128.8 101 74 - 766
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on ICU bed availability and according to local protocols, four of 
these patients were refused ICU admission on the basis of being too 
ill and ultimately died. Two were accepted to the ICU, of whom one 
survived and the other died. The mortality rate in patients requiring 
ICU admission for organ support was 83.3%.
Predictors of outcome
There was no difference between the mean age of survivors and 
non-survivors (p=0.752), and no association between mortality and 
comorbidity (p=0.566) or number of debridements (p=0.087).
There were sufficient data to calculate the FGSI retrospectively 
in 31 patients. The median FGSI was 6 (range 0 - 20). The mean 
(standard deviation) FGSI differed significantly between patients 
who died (15.4 (4.78)) and those who survived (5.92 (4.09)) 
(p<0.001). There was a significant association between FGSI >9 
and mortality (p=0.017). FGSI >9 predicted 44.4% mortality, and 
FGSI ≤9 predicted 95.5% survival. A combination of FGSI >9, 
debridement outside the perineum (onto the abdominal wall, chest 
or limbs) and requirement for organ support was present in 80.0% 
of the patients who died.
The parameters assessed as risk factors for mortality on univariate 
logistic regression are summarised in Table 4.
Of the parameters in Table 4, only requirement for organ support 
was a significant risk factor for mortality on multivariate analysis 
(p=0.043). When FGSI >9, debridement outside the perineum and 
requirement for organ support were replaced in the multivariate 
regression by a single parameter that was positive only when these 
three conditions were met, this parameter was a significant risk factor 
for mortality (p=0.002).
Outcomes in HIV- and DM-affected patients
There was a 14.3% mortality rate among HIV-positive patients and a 
16.7% mortality rate among those with DM. Neither HIV (p=0.658) 
nor DM (p=0.386) was significantly associated with mortality. 
Patients with only DM were significantly more likely to need two 
or three debridements (p=0.001), whereas the majority of patients 
without DM (92.3%) required only one debridement. DM patients 
were significantly more likely to develop AKI (p=0.031), but neither 
HIV nor DM was significantly associated with the need for organ 
support.
Definitive management
Most patients were managed at the tertiary centre with wound care, 
and ultimately went on to have skin grafts for coverage. Those with 
urethral strictures as the initiating event and those who went on to 
develop urethral strictures were planned for additional procedures to 
manage the strictures.
Fig. 3. A patient with extensive debridement of the left iliac fossa, immediately 
after debridement.
Table 4. Parameters tested for association with mortality on univariate logistic regression
Parameter OR 95% CI for OR p-value
Age >60 years 1.5 0.221 - 10.171 0.678
DM 2.4 0.358 - 16.077 0.367
HIV 1.75 0.263 - 11.662 0.563
Lactate ≥3 mmol/L 13.5 1.340 - 135.983 0.027*
FGSI >9 16.8 1.526 - 184.921 0.021*
Debridement outside perineum 11.6 1.156 - 116.417 0.037*
≥2 debridements 4.35 0.633 - 29.914 0.135
Requirement for organ support 90 6.845 - 1 183.325 0.001*
FGSI >9, debridement outside perineum and requirement for organ support 152 7.899 - 2 924.764 0.001*
OR = odds ratio; CI = confidence interval; DM = diabetes mellitus; FGSI = Fournier’s gangrene severity index.
*Significant at p<0.05.
Fig. 4. The same patient as in Fig. 3 after wound care, prior to skin grafting.
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Discussion
In developing countries such as SA, poor socioeconomic conditions, 
limited access to healthcare, a high prevalence of HIV infection and 
an increasing prevalence of lifestyle diseases such as DM result in 
FG remaining an important clinical condition. It was not possible to 
calculate the incidence of FG in the present study, as Grey’s Hospital 
is not the only hospital in the drainage area at which FG cases are 
treated. However, the caseload of 8.8 cases per year is certainly high. 
Sorensen and Krieger[12] reviewed 1 641 men with FG in the USA and 
observed that only 1% of hospitals in that country treated >5 cases of 
FG per year.
It has been well established that FG is associated with an underlying 
systemic condition that impairs host immunity.[3,4] In the present 
study, HIV was the most common comorbidity, with 47.7% of 
patients being HIV-positive. This rate of HIV infection is higher 
than seen in other large studies. Ngugi et al.[13] reviewed 146 patients 
presenting with FG in Kenya and found an HIV rate of 16.4%. Chalya 
et al.[14] reviewed 84 patients with FG in Tanzania and found an HIV 
rate of 11.3%. SA has the highest prevalence of HIV in the world, so 
this finding is not surprising.
The mean age of presentation across all patients in the present 
study was 51 years. This is in line with other large studies. The mean 
age of the 1 641 men with FG in Sorensen and Krieger’s[12] study was 
50.9 years. In the present study, HIV-positive patients presented at a 
younger age (mean 41 years) than non-HIV positive patients. Ngugi 
et al.[13] found HIV to be the commonest underlying comorbidity in 
their Kenyan study, in which the patients had a mean age of 35 years. 
Elem and Ranjan[6] reviewed 10 cases at a single hospital in Zambia 
and found 80% to be HIV-positive, with a median age of 34.5 years 
for the HIV-positive patients. These two studies did not compare the 
age of presentation in HIV-positive and HIV-negative patients, but 
still add credibility to the conclusion that HIV-positive patients are 
likely to present at a younger age.
All patients in the present study were initially treated with broad-
spectrum antibiotics. The most common choice was co-amoxiclav, 
metronidazole and gentamicin. FG is well known to be a synergistic 
polymicrobial infection, and generally not all organisms involved are 
identified in cultures.[3] Broad-spectrum empirical antibiotic cover 
that includes Gram-positive, Gram-negative and anaerobic organisms 
is therefore necessary. The hospital protocol of co-amoxiclav, 
gentamicin and metronidazole seems to be reasonable empirical 
therapy for FG.
Although FG is rare, each case treated places a resource burden on 
the health system. The mean LoS in the present study was 26 days. 
In referral centres where bed occupancy rates are high, prolonged 
admissions increase bed pressure. Furthermore, patients with FG 
needed on average 1.33 surgical procedures each during their initial 
management, not considering additional procedures for skin grafting 
and management of complications. Nearly half of the patients were 
transfused, and 13.6% were identified as requiring ICU admission. 
These activities, along with other resources utilised, result in an 
inflated cost per admission in FG patients. Jiménez-Pacheco et al. [15] 
investigated the cost of an FG admission in a Spanish study and 
found a cost of EUR25 108.67 per admission for a patient requiring 
ICU admission and at least one surgical procedure. They concluded 
that the cost was high and justified implementation of primary and 
secondary prevention measures.
The prolonged LoS in the present study is not unique, particularly 
compared with developing countries. Mean LoS was 28 days in 
a Zambian study,[6] 37.1 days in a Nigerian study,[16] 23.2 days for 
patients with complications in a Kenyan study,[13] and 28 days in 
a Tanzanian study.[14] Mean LoS was even high (27.5 days) in a 
Spanish study.[15] In contrast, in Sorensen and Krieger’s[12] study in 
the USA, mean LoS was 10 days for teaching hospitals and 7 days for 
non-teaching hospitals. This difference is probably explained by far 
distances to referral centres and lack of capacity at district hospitals 
in developing countries, hindering downward referral.
FG is well known to be associated with a high risk of mortality. 
The overall mortality rate in the present study was 11.4%, which is in 
line with other studies. Sorensen and Krieger[12] analysed 59 FG case 
series published between 1972 and 2015 and found a mortality rate 
ranging between 0% and 88%. In their review of 1 641 men with FG 
in the USA, they found an overall case fatality rate of 7.5%. Eke[17] 
reviewed 1 726 cases of FG in a meta-analysis and found a mortality 
rate of 16%.
In the present study, neither HIV nor DM was significantly 
associated with increased mortality. This finding is surprising, given 
the immune compromise associated with these conditions.[3,4] HIV 
with a low CD4+ count was found to be significantly associated 
with increased mortality by Chalya et al.[14] There was also no 
association between age and increased mortality, which is surprising, 
because older patients would be expected to cope less well with the 
physiological derangements associated with FG. Other studies have 
found that younger patients are more likely to survive than older 
patients.[2,15,18-20] The likely explanation for these observations is that 
the small sample size of patients who died precluded a demonstrable 
correlation between mortality, comorbidity and age.
Owing to the frequent need for referral and the challenge of 
allocating resources in a resource-constrained environment, tools 
that enable outcome prediction are important in conditions such 
as FG. A number of these have been assessed, including the FGSI, 
Uludag FGSI (FGSI with age and extent of disease scores added), 
Age-adjusted Charlson Comorbidity Index (ACCI) and Surgical 
Apgar (sAPGAR) Score.[19] The affected body surface area[21] and the 
Laboratory Risk Indicator for Necrotising Fasciitis (LRINEC)[22] have 
also been assessed. These tools can be used at the bedside to score 
patients and assist with decisions to refer to a higher centre, admit 
to ICU or withhold treatment. In the present study, the FGSI was 
automatically calculated using a formula in Microsoft Excel. This 
could easily be incorporated into a mobile phone app or website and 
made accessible to doctors to use when managing patients with FG.
Of the scoring tools available, the FGSI has been the most 
investigated. It was described by Laor et al.[2] in 1995 and is based on 
the Acute Physiology and Chronic Health Evaluation II (APACHE 
II) score. The utility of the FGSI has been validated by a number of 
studies[23-29] showing a correlation between FGSI and mortality, and a 
threshold of 9 as being sensitive and specific for predicting mortality. 
Roghmann et al.[19] found that simpler scores such as the sAPGAR 
and ACCI were equivalent to the FGSI and UFGSI scores,[19] but did 
not find the FGSI to be inferior. Other studies have shown that the 
FGSI is unable to predict disease severity and survival.[30-32] Tuncel 
et al.[20] concluded in a subsequent study that addition of age and 
involved surface area parameters was necessary to predict mortality.
In the present study, the percentage area involved was not recorded 
routinely in the patient notes. As a result, neither this parameter nor 
the UFGSI could be calculated. The mean FGSI was significantly 
different between survivors and non-survivors. An FGSI cut-off 
of 9 was significantly associated with mortality. Additional factors 
that were associated with mortality on univariate analysis were a 
lactate level of >3 mmol/L, debridement outside the perineum and 
requirement for organ support in the ICU. Debridement outside 
the perineum is an indicator of extensive disease, and our finding 
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that it was a risk factor concurs with other studies showing that the 
percentage of body surface area affected is a predictor of mortality.[21] 
The only risk factor that remained significant on multivariate analysis 
was requirement for organ support. The multivariate analysis was 
limited by the small sample size, particularly in the group of patients 
who died.
A combination parameter including FGSI >9, requirement for 
organ support and extension outside the perineum was a significant 
risk factor for mortality. Based on validations of the FGSI in the 
literature and the findings of the present study, it appears that a 
scoring system for decision-making in FG must incorporate acute 
physiological derangement, extent of body surface area involvement 
and organ failure. The present study validates the FGSI in the 
SA population. It also supports the concept of adding additional 
parameters to the FGSI to better predict mortality, in this case 
presence of organ failure and disease extent. In the resource-
constrained SA environment, use of such a scoring system is likely 
to be useful in ICU bed and emergency theatre allocation when 
there are often multiple patients competing for a single resource, and 
patients with a high risk of mortality could potentially be offered 
palliative care.
Conclusions
FG remains a condition with a high mortality rate, and the caseload 
at an SA tertiary referral centre is high. HIV-positive patients present 
at a younger age but do not have worse outcomes. Patients with DM 
also do not have worse outcomes, but require more debridements 
and are more likely to develop AKI. In a resource-constrained 
environment, outcome prediction is necessary to enable resource 
allocation. The FGSI successfully predicts increased mortality 
using a threshold of 9. Patients with an FGSI >9 have a high risk 
of mortality and will benefit from ICU care. The combination of 
FGSI >9, requirement for organ support and extension beyond the 
perineum (onto the abdominal wall, chest or limbs) is associated 
with a very high risk of mortality and may be useful as an exclusion 
criterion when allocating scarce resources.
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